New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 19, 2021 - The FDA announced the approval of BioMarin’s Voxzogo (vosoritide), to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.
Download PDF
Return to publications
